All Brands Owned by Johnson & Johnson

Is Johnson & Johnson publicly traded?
Yes, Johnson & Johnson is publicly traded on the New York Stock Exchange under the ticker symbol JNJ. The company has been publicly traded since 1944 and is one of the most widely held healthcare stocks globally, included in major stock market indices including the Dow Jones Industrial Average.

What were Johnson & Johnson's FY2025 financial results?
J&J reported full-year 2025 sales of $94.2 billion, up 6.0% year-over-year, with net earnings of $26.8 billion and adjusted EPS of $10.79. Q4 2025 sales grew 9.1% to $24.6 billion. The company generated approximately $19.7 billion in free cash flow and increased its dividend for the 63rd consecutive year.

Who is Johnson & Johnson's CEO?
Joaquin Duato serves as Chairman and CEO of Johnson & Johnson. He became CEO in 2022 and described 2025 as a "catapult year" fueled by the strongest portfolio and pipeline in the company's history. Duato has focused J&J on six key therapeutic areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision.

What is Johnson & Johnson's 2026 outlook?
J&J issued 2026 guidance of $100.5 billion in estimated reported sales (6.7% growth at midpoint) and adjusted EPS of $11.53 (6.9% growth at midpoint). This guidance accounts for approximately $500 million in expected tariff impacts and a drug pricing agreement with the Trump administration.

What are Johnson & Johnson's main business segments?
J&J operates through two segments: Innovative Medicine (pharmaceuticals), which generated $60.4 billion in 2025 sales, and MedTech (medical devices), which contributed $33.8 billion. The company previously had a third Consumer Health segment, which was spun off as Kenvue in 2023.

What happened to Johnson & Johnson's consumer brands?
In 2023, J&J completed the spin-off of its consumer health business as Kenvue, which included Tylenol, Band-Aid, Johnson's Baby, Neutrogena, Aveeno, Listerine, and other consumer brands. Kenvue was fully separated in August 2023 via an IPO and exchange offer. These brands remain associated with J&J in public recognition.

What medical innovations did J&J achieve in 2025?
J&J secured FDA approval of CAPLYTA for major depressive disorder, approval of RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer, and reported landmark data for TECVAYLI plus DARZALEX FASPRO for multiple myeloma. The company also acquired Halda Therapeutics and submitted the OTTAVA Robotic Surgical System for regulatory review.

What is the talc litigation status?
J&J faces thousands of lawsuits alleging its talc-based baby powder caused ovarian cancer and mesothelioma. In October 2025, a California jury awarded $966 million to a mesothelioma victim's family. In March 2025, a bankruptcy judge rejected J&J's proposed $8 billion settlement for ovarian cancer claims. The litigation remains ongoing.